TL;DR: Arterial insufficiency wounds heal poorly when tissue oxygen stays too low. Hyperbaric oxygen therapy (HBOT) is a UHMS-recognized adjunct for selected problem wounds tied to arterial insufficiencies, and Medicare lists acute peripheral arterial insufficiency among covered HBOT indications. Care still starts with vascular assessment and, when needed, revascularization. HBOT does not replace those steps. Transcutaneous oxygen testing helps select patients most likely to benefit. OxygenWell offers medical-grade HBOT at Sherman Oaks and Calabasas for patients referred for qualifying wound and ischemia pathways.

What arterial insufficiency means for a wound

Arterial blood delivers oxygen and nutrients to skin and soft tissue. When peripheral arteries narrow or block, downstream tissue becomes hypoxic. Problem wounds then stall: infection control weakens, collagen deposition slows, and angiogenesis falters.

The Undersea and Hyperbaric Medical Society (UHMS) describes this pathway clearly: hypoxia in the wound bed correlates with impaired healing and higher infection risk, and oxygen-sensitive steps such as fibroblast activity, collagen deposition, angiogenesis, and leukocyte bacterial killing depend on adequate oxygen availability. (UHMS: Enhancement of Healing in Selected Problem Wounds)

Peripheral arterial occlusive disease is common and progressive. It can lead to critical limb ischemia, non-healing ulcers, and amputation risk, and it often complicates venous and diabetic foot ulcers as a comorbidity. (UHMS)

Arterial ulcers vs venous ulcers (quick clinical picture)

Patients and referrers often search "arterial ulcer treatment" because leg wounds look similar at first glance. Patterns differ:

• Arterial ulcers tend to sit on toes, heels, or bony prominences; they can appear deep with pale, yellow, or necrotic bases; surrounding skin may look shiny or hairless; the limb can feel cool; pain often worsens with elevation or at night. (Healthline overview of arterial vs venous ulcers)
• Venous ulcers more often appear on the medial lower leg, with edema, hemosiderin staining, and pain tied more to inflammation and venous hypertension than pure ischemia. (PMC: Venous and arterial leg ulcers)

Mixed arterial-venous disease is common. That is why vascular workup matters before compression or any adjunct oxygen plan.

Where hyperbaric oxygen fits (UHMS framing)

UHMS groups selected problem wounds under arterial insufficiencies and "enhancement of healing in selected problem wounds." The society notes that while basic science supports HBOT across many hypoxic wounds, the strongest clinical evidence base has historically centered on ischemic, infected diabetic foot ulcers (Wagner grade III or worse), with ongoing need for more trials in other ischemic non-diabetic ulcers. (UHMS indications chapter)

In plain terms: HBOT is not a first-line fix for every leg ulcer. It is an adjunct when tissue hypoxia is a rate-limiting barrier after standard wound and vascular care.

Reviews aimed at surgical audiences also list non-healing diabetic and vascular insufficiency ulcers among wound types where HBOT has been used successfully as adjunctive therapy, with patient selection often guided by transcutaneous oximetry. (PMC: Hyperbaric oxygen and wound healing)

How HBOT changes oxygen delivery in ischemic tissue

During HBOT, the patient breathes near-100% oxygen inside a pressurized chamber. UHMS explains the physiology in practical terms:

• Raised ambient pressure multiplies dissolved oxygen in plasma, which can raise arterial PO2 into the range of roughly 1500 mmHg or greater at about 2.0-2.5 ATA.
• That dissolved fraction reaches poorly perfused tissue more readily than hemoglobin-bound oxygen alone.
• Intermittent hyperoxia supports leukocyte bacterial killing, can potentiate certain antibiotics, blunts aspects of ischemia-reperfusion inflammation, and stimulates growth signaling including VEGF-related angiogenesis pathways over a series of treatments.
• Stem/progenitor cell mobilization has been observed across courses of HBOT in related soft-tissue indications (including CD34+ cell increases across multi-session courses in published hyperbaric research summarized by UHMS).

Source: UHMS physiology section on hyperbaric oxygenation of wounds.

Important clinical nuance from the same UHMS review: restoring "normal" oxygen for a few minutes is not the whole story. Benefit often tracks with achieving high tissue oxygen levels during treatment (for example, periwound PtcO2 responses under hyperbaric conditions), which supports signaling and host-defense effects beyond brief normoxia.

Patient selection: why PtcO2 (TCOM) matters

Transcutaneous oxygen tension (PtcO2 or TCOM) measures oxygen availability near the wound. UHMS and wound-care literature treat it as a practical tool to:

• Flag occult peripheral arterial disease around a wound
• Estimate risk of primary healing failure or amputation flap failure
• Help judge whether a trial of HBOT is realistic

UHMS summarizes key thresholds used in practice (values vary by lab technique, but patterns are consistent):

• Periwound hypoxia in the roughly <25-40 mmHg range associates with poor spontaneous healing of wounds and flaps; lower values track with greater impairment.
• Pecoraro and colleagues reported a large jump in primary healing failure risk when periwound PtcO2 fell below 20 mmHg (about a 39-fold increased risk in that series, as cited by UHMS).
• In a large diabetic foot ulcer HBOT series (n=1144) summarized by UHMS: sea-level air PtcO2 defines hypoxia but poorly predicts who will respond to HBOT; breathing 100% O2 at 1 ATA with PtcO2 <35 mmHg associated with higher subsequent HBOT failure (~41%) versus higher values (~69% benefit likelihood); in-chamber PtcO2 >200 mmHg was about 74% reliable for predicting healing improvement or limb salvage in that analysis; failure to rise above ~100 mmHg under hyperbaric conditions is a concerning predictor, though a short therapeutic trial is sometimes still considered when the alternative is amputation.

Source: UHMS PtcO2 guidance. Plastic surgery-oriented reviews similarly emphasize TcPO2-guided selection for HBOT in non-healing wounds. (PMC review)

Does the evidence always show benefit?

Be honest with patients: results depend on vascular status, infection control, offloading, nutrition, and whether the protocol can be completed.

The DAMO2CLES multicenter randomized trial enrolled 120 patients with diabetes and ischemic lower-extremity ulcers. Adding HBOT to standard care did not produce a statistically significant improvement in complete wound healing or limb salvage at 12 months in the intention-to-treat analysis. About 35% of patients assigned to HBOT could not complete the planned protocol; those who completed HBOT had fewer major amputations and higher amputation-free survival in secondary analyses. (Santema et al., Diabetes Care 2018, DAMO2CLES)

Takeaway for referral conversations: HBOT is a tool inside a full limb-preservation plan, not a stand-alone promise. Candidates need realistic session logistics and concurrent vascular/wound optimization.

Medicare and insurance: acute peripheral arterial insufficiency

Medicare Part B may cover HBOT delivered in a chamber when the patient has a listed condition. The official Medicare coverage page includes acute peripheral arterial insufficiency on that list, alongside other UHMS-aligned indications such as crush injury/acute traumatic ischemia, compromised skin grafts, diabetic lower-extremity wounds meeting Wagner and failed-standard-care criteria, and delayed radiation injuries. (Medicare.gov: Hyperbaric oxygen therapy coverage)

Commercial policies vary. Some carriers define acute peripheral arterial insufficiency narrowly (for example, cases requiring emergent surgical or catheter intervention with imaging documentation of embolus/thrombus and a limited number of perioperative HBOT sessions). Chronic arterial ulcers without an acute ischemic event may fall under different pathways (diabetic Wagner criteria, compromised flap, etc.) or may not meet that carrier's criteria. Always verify the patient's plan and documentation needs before starting. (Example commercial policy language, Aetna CPB 0172)

OxygenWell's billing partners handle pre-authorization for qualifying FDA/Medicare-aligned pathways. Patients can start with our Medicare HBOT coverage guide and the insurance page.

What a typical care pathway looks like

1. Vascular assessment: pulses, ABI/TBI when appropriate, imaging, and revascularization referral if flow can be improved.
2. Wound fundamentals: debridement as indicated, infection control, glycemic optimization in diabetes, pressure relief, nutrition.
3. Objective hypoxia check: TCOM/PtcO2 around the wound, sometimes with oxygen challenge.
4. HBOT trial when indicated: medical-grade monoplace chamber sessions (OxygenWell delivers 100% medical-grade oxygen via non-rebreather mask, pressures up to 2.4 ATA) on a multi-week schedule set by the referring plan and response.
5. Reassess early: wound measurements, infection status, and oxygen response; continue, adjust, or stop based on trajectory.

Related reading on our site: HBOT for diabetic foot ulcers, crush injury and acute traumatic ischemia, and compromised skin grafts and flaps.

Who should ask about HBOT for arterial-related wounds?

• Patients with non-healing lower-extremity wounds and known PAD or critical limb ischemia under active vascular care
• Diabetic foot ulcers that meet severity criteria after standard wound therapy fails
• Acute ischemic events of the extremities when the surgical team includes HBOT in the perioperative plan
• Patients facing major amputation discussions where tissue oxygen salvage is still on the table

HBOT is not appropriate for every chronic leg wound. Stasis ulcers alone and many purely venous wounds without a covered indication are outside typical Medicare HBOT lists. (Medicare coverage list)

OxygenWell in Los Angeles: Sherman Oaks and Calabasas

OxygenWell is a hyperbaric and regenerative medicine center serving Los Angeles from Sherman Oaks and Calabasas. We focus on medical-grade chambers rated to full treatment pressures, safety-first operations led by experienced hyperbaric technicians (many EMT-certified), and coordinated care with referring vascular, wound, podiatry, and surgical teams.

If you or your patient has an ischemic or arterial-insufficiency wound pathway under evaluation, contact us to discuss whether HBOT documentation and scheduling fit the case. Call (818) 661-0939 or visit oxygenwell.com/contact.

Key takeaways

• Arterial insufficiency drives wound hypoxia; hypoxia blocks core healing biology.
• UHMS frames HBOT as adjunctive enhancement of healing in selected problem wounds related to arterial insufficiencies, with the best evidence density in ischemic infected diabetic foot ulcers.
• PtcO2 helps identify hypoxia and refine HBOT candidacy.
• Medicare includes acute peripheral arterial insufficiency among chamber HBOT covered conditions; commercial rules differ, verify before treatment.
• Randomized data (DAMO2CLES) show mixed intention-to-treat results in ischemic diabetic ulcers, with stronger signals among protocol completers, reinforcing patient selection and concurrent standard care.

Educational content only. Not a substitute for personal medical advice. Treatment decisions belong to the patient and their clinical team.